Skip to main
DHR
DHR logo

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 41%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Danaher Corporation has demonstrated a positive trajectory with its performance obligations rising to $4.9 billion in 2Q25 from $4.5 billion in the previous quarter, indicating strong future revenue potential. The company expects a 4.5% growth ramp in its Life Sciences segment for 4Q25, which is supported by favorable comparisons in Genomics and new product launches. Additionally, the anticipated revenue from Cepheid Respiratory for 3Q25 and 4Q25, estimated at $300-350 million and $450-500 million respectively, underscores Danaher's improving market position within the diagnostics industry.

Bears say

Danaher's projected revenue recognition for 2Q25 reflects a decline, with only 46% of obligations expected to be recognized within the next 12 months, down from 48% in the previous quarter. The company faces significant risks related to geopolitical disruptions, foreign exchange volatility, and the potential failure of high-growth end-markets, particularly in China, to recover. Additionally, any changes to the forecasted end-market growth rates could further exacerbate financial performance concerns, highlighting uncertainty in the company's future revenue stability.

Danaher (DHR) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 41% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 17 analysts, Danaher (DHR) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $246.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $246.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.